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Cytotoxic T cell (CTL) is the key to induce an effective immune response 
against infections caused by intracellular pathogens, such as virus and cancer. CTLs 
with low affinity can induce and maintain a substantial population during an adaptive 
immune response, although CTLs with a highest-affinity receive competitive activation 
signals. Low-affinity CTLs are important to induce effector response and maintain a 
diverse memory repertoire. However, the mechanism of generating and maintaining 
the expansion of lower affinity CTLs is still unknown. Here, we showed that the 
presence of exosome (Exo) enhanced the CTL survival and increased the cell 
proliferation especially in CTLs treated with the low-affinity peptide.  Exo together 
with peptides also improved the production of IFN-γ and GZB.  The exosomal 
stimulation in CTLs was relative to up-regulation of CD25 expression, which enhanced 
the IL-2 survival signals. Moreover, Exo derived from an early stage of activation had 
a similar but weaker function comparing with Exo derived from a late stage of 
activation in activating CTLs. This study identified the important role of the exosome 
derived from CTLs stimulated by the highest-affinity peptide in activating the naïve T 
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Chapter 1: Introduction 
Introduction of Cytotoxic T Lymphocytes (CTLs) 
T cells develop in the thymus where they start to proliferate, differentiation and 
undergo a series of selection processes to obtain mature single positive (CD4+ or 
CD8+) T cells [1]. Mature T cells play a leading role in adaptive immunity against viral 
infection and cancer. CD8+ T cells, or so-called CTLs, are the key player in recognizing 
through TCR ligation, and killing infected or malignant cells through direct lysis, 
secreting antiviral cytokines and killing-related molecules, like perforin and granzymes 
(GZB) [1]. CTLs can also trigger cell apoptosis in a target cell through secretion of Fas 
and APO2L. As a result, CTLs are responsible for the destruction of cells infected by 
intracellular pathogens or malignant tumor cells via cytotoxic activity and antitumor 
immunity.  
Once the pathogen is eliminated, a dramatic contraction of cell number happens 
and most of CTLs (around 90%) will undergo programmed cell death. Only a small 
population of CTLs will survive for a long-term as memory T cells. When encountering 
the same or similar antigen, memory T cells can react against secondary infection by 
providing faster, more robust and more effective immune response [1]. It is the 
fundamental principle for the vaccination development.  
Due to the contribution to our immunity, CTLs are thought as a promising target 
for disease treatment and vaccine development, and many types of research are aimed 





T-cell activation and three signals  
Naïve T cells need to be activated to undergo clonal expansion, develop 
functions and generate a long-term memory population after the clearance of antigen. 
Therefore, three kinds of signals are critical to activating naïve CTLs. 
Traditionally, the full activation first requires T-cell receptors (TCRs) to 
recognize an antigen presented by antigen presenting cells (APCs), often from activated 
dendritic cells. Each T cell possesses a unique TCR to specifically recognize a foreign 
antigen. TCRs are expressed on the surface of a T cell and they are highly variable and 
unable to bind to antigen directly like the antibody. Therefore, TCRs need APCs to 
present broken-down peptides of antigens from pathogens through binding to major 
histocompatibility complexes I (MHC I). In addition, the pMHC/TCR interaction is 
very sensitive and the optimal kinetic is an important factor of T cell activation. For 
example, short time (less than 6hrs) exposure to antigen is enough to induce naïve 
CD8+ T cells to undergo multiple rounds of cell division [2, 3]. However, Mescher and 
his team have shown that T cells only exposed to antigen for a short-term did not 
survive and limited the colony expansion and impaired the effector function [4]. In 
order to further enforce the interaction, several adhesion molecules help to promote 
cell-cell adhesion and to respond to signaling via TCR [5]. In short, the formation of 
conjugation between a TCR on T cell and a peptide held in the MHC on APCs provide 
the first signal to initial activation of T cells and the interaction between TCR and 
antigen/MHC is very important. 
Next, a second signal referred as co-stimulation and several cytokine signals 




provided by dendric cells [7, 8]. Notable costimulatory molecules such as CD28, 
lymphocyte function-associated antigen 1 (LFA-1), and intercellular adhesion 
molecule 1 (I-CAM) are essential for T cell activation [9]. CD28 is a glycoprotein 
expressing constitutively on the surface of human T cells and on most of the murine T 
cells and can significantly enhance the downstream signaling from the triggered TCRs 
by simultaneously engaging with the cognate ligands B7.1 and B7.2 expressed on 
APCs [10]. Some see interleukin-2 (IL-2), which signals through Janus kinase (JAK) 
[11], as the T cell growth factor that help T cells to undergo several rounds of cell 
proliferation and enhance the naïve T-cell survival in non-lymphoid tissues.[12]. The 
other helping cytokine signals, like IL-12 and Type 1 IFNs, are serving as the third 
signal [13-16]. Previous studies have shown that the third signal is required for optimal 
activation, induction of effector function, improvement of colony expansion and 
priming into memory T cell [15, 16].  
After an encounter with the appropriate antigen, co-stimulation and 
inflammation cytokines, T cells undergo vigorous clonal expansion, transcriptional, 
epigenetic and metabolic reprogramming and acquire effector functions. This 
activation, or ‘priming’, will determine the fate of naïve CD8+ T cells, and whether 
they will initiate the differentiation and the T cell function [1]. 
After activation, the effector T cells become cytotoxic and can produce multiple 
cytokines like interferon-γ (IFN-γ) [17], tumor necrosis factor (TNF) and IL-2. 
Cytokines produced by T cells or other immune cells can mediate direct effects on 
cytotoxic effects or assist in activating T cell. After activation, T cells will perform cell-




perforin and proteases, granzyme B, to trigger programmed cell death in the target cell. 
Another secreted substance, Fas ligand, can also activate certain caspases to induce cell 
apoptosis [18]. Once antigen and/or inflammation are cleared and return to 
homeostasis, a large-scale apoptotic episode occurs, and most activated T cells die. 
During this transition state from the effector expansion phase into the contraction 
phase, a small population of T cell subsets escapes death and remains as a stable 
population of memory T cells. The functional memory CD8+ T cells persist and 
maintain the ability to recall rapidly activated effector functions upon secondary 
infection. 
Several parameters determine the fate and magnitude of T cell activation. 
Insufficient activation will restrict proliferation and colony expansion, deplete 
cytotoxic effector function and impair cytokine production. This T cell dysfunction, 
including exhaustion, tolerance, anergy, and senescence, impedes the immune 
protection and fails to clean the infection. Moreover, inadequate exposure to the third 
signal will result in a tolerance state which often develops into a chronic disease [4]. 
On the other hand, over-activation will lead to autoimmune disease. Therefore, 
achieving optimal activation of CD8+ T cells is a critical issue in defending infection 
and disease.  
 
pMHC/TCR affinity in the CTL activation  
How to achieve the optimal activation of CTLs cell is puzzling. However, naïve 
T cell activation is strictly dependent on the affinity of antigen recognition via pMHC 




recognize short peptide fragments of pathogen protein antigens which are bound to 
MHC molecules on the surfaced of antigen presenting cells (APC). MHC molecules 
have a cleft running across their surface where a various peptide can bound. Each MHC 
molecules can carry up to 12 of the possible variants allowing a wide range of peptides 
that bond to MHC [19]. CTLs recognize the peptide/MHC complex through TCR 
which expressed at the cell membrane as a complex with CD3 chains. TCR is 
membrane‐bound complexes and consists of a disulfide-linked heterodimer with an 
amino‐terminal variable (V) region and a carboxy‐terminal constant (C) region [20].  
A binding groove will form during the TCR recognition where TCR directly interact 
with both MHC helices and peptide [1]. The binding of TCR to peptide/MHC complex 
with high affinity results in transduction of activation signals and lead to CTL immune 
response like proliferation and differentiation.  
The strength and the binding ability of the TCR/pMHC interaction can be 
determined by the affinity. As a result, the affinity of pMHC/TCR interaction is the 
primary determinant of T cell response and the strength of activation [21, 22]. The 
specificity of peptide-dependent TCR recognition triggers signal transduction and the 
highest affinity peptide will receive the competitive advantage of signaling which 
stimulates vigorous proliferation [23, 24].  There are many factors will influence the 
pMHC/TCR affinity measuring through surface plasmon resonance (SPR) 
measurement, micropipette adhesion assay and tetramer binding assay [25, 26]. 
Research has found that peptide sequence plays an important role in pMHC-TCR 
affinity [27]. When the peptide sequence of TCR ligand is altered, it will result in 




proliferation [28, 29] Any change of pMHC/TCR sequence would greatly alter the 
binding ability[30] by reducing the binding energy [26, 31], and consequently change 
the T cell response and T cell functional capacity [24, 32]. Also, if the peptide sequence 
of MHC anchor residue was altered, the binding ability was changed, and T cell would 
lose the ability to recognize the foreign peptide. Therefore, the amino acid position is 
highly specific to T cell recognition. When the antigen was altered in sequence to 
increase the affinity toward TCR, this stronger binding resulted in stronger T cell 
responses including activation of nuclear factor of activated T-cells (NFAT) and 
expression of IL-2 [33]. Many studies have shown high-affinity of pMHC/TCR 
interaction were important to maintain continued CTL response [30] since it will result 
in enhanced survival during infection [21, 34]. Also, there is a strong co-relation 
between affinity and proliferation [35, 36]. Therefore, many studies are aiming to 
design the highest affinity molecules to optimize the therapeutic efficacy by improving 
T cell function and proliferation [37].  
However, both high-affinity and low-affinity CTLs share the naive repertoire 
in the real word. During an immune response, low-affinity CTLs can still response and 
sustain a substantial population [30, 38] even though they receive defective activation 
signals comparing with high-affinity CTLs in polyclonal T-cell responses [30]. 
Although the function of low-affinity CTLs and their frequencies in polyclonal T cell 
response is still unclear, many studies have shown that low-affinity CTLs are important 
to induce the effector function of CTLs and play an important role against infection[30, 
38, 39].  For example, low-affinity CTLs also develop the effector function while the 




developed into asymmetric cell division while T cells with lower affinity underwent 
symmetric division. Moreover, T cells with higher affinity displayed higher surface 
expression of CD25, CD69 and IFN-γ and vigorous proliferative response and 
differentiate into tissue-infiltrating effector T cells but T cells with lower affinity fail 
to do this [27]. Mice in vivo stimulated with lower-affinity peptide induced CTLs 
response that was relative to the development of autoimmunity upon infection [40]. 
This indicated the potentially different roles and pathways of activating the low and 
high-affinity T cells [38]. Although low-affinity peptide stimulation could induce the 
CTL proliferation, the effector function of T cell was limited. Low-affinity CTLs 
reached the division limitation earlier than high-affinity CTL and stronger activation 
signals must be delivered in order to prevent the impaired effector function like a 
production of cytokine and cytotoxic molecules [30]. Therefore, identifying the 
potential assistance to help the activation of CTL is needed.  
 
 Transcription factors of CTLs  
To maximize the T cell expansion and effector function, activation of T cell 
induces several transcription factors like T-bet. They play an important role in effector 
function and regulating the formation of long-term memory in murine T 
lymphocyte[41, 42]. T-bet, a T-box transcription factor in T cell, T-bet was first found 
in the murine Brachyury gene. The following research showed T-bet is closely 
associated with promoting T-cell development into effector T cell and maintenance of 
memory T cell repertoire. The T-bet expression level determined the differentiation of 




T-bet expression results in increased secretion of perforin and granzyme B [44]. 
Moreover, T-bet modulated cell signaling in IL-12 and IL-2 [45]; and positively 
influenced the IFN-γ production [46]. T-bet also help the T cell mobilization through 
CRCR3 signaling. Lastly, evidence has emerged that T-bet helped the adaptive cell-
mediated immunity against tumor by improving the infiltration and migration of CD8+ 
T cells to the tumor sites [47]. In conclusion, T-bet is a key transcriptional drivers of 
lymphocyte differentiation, proliferation and development effector function.  
 
Introduction of Exosome  
Exosomes are a subset of extracellular vesicles (EVs). They are best defined as 
small round-shaped membrane-bound vesicles of 30–150 nm in diameter, appearing 
with a lipid bilayer structure [48-50].  
Extracellular vesicles were discovered more than 50 years ago, from the study on 
the maturation of rat erythrocytes [51]. The Further demonstration showed consistent 
results that transferrin and its receptor, a marker of reticulocytes maturation, were 
recycled back to the plasma membrane after endocytosis and indicated the unique 
mechanism of selective externalization [52]. Later, Johnstone and his team confirmed 
that that liberated intraluminal vesicles (ILVs) generated in multivesicular bodies 
(MVBs) could be released to the extracellular environment through fusion with the 
plasma membrane (Johnstone 1987). These small-sized vesicles released into the 
extracellular milieu are the original detailed description of what we know as exosomes 




After a decade, several ground-breaking researchers discovered the unique role of 
exosomes in immunity and focused attention on this. For example, it has been shown 
that B lymphocytes release similar vesicles bearing antigen-presenting molecular to 
alter T cell response [53]. The following study indicated a novel means of genetic 
information transferring through exosome exchanging the mRNA and microRNA 
between parent and recipient cells [54, 55]. Function and application of exosome have 
increased from that time. Therefore, exosomes, initially considered as a means of 
cellular waste disposal from reticulocytes, were largely ignored; now they draw 
enormous attention since they are thought as a cell-to-cell communication, signal 
mediation, the disease diagnoses, and as a potential for drug development.  
 
Biogenesis and sorting mechanism of exosome 
Exosomes originate in endosomal compartments called MVBs. MVBs form 
during the maturation of endosomes and they can be visualized by electron microscopy 
(EM) with size 100–600 nm, and size around 50 nm ILVs are present in MVBs. Some 
MVBs end up fusing with lysosomes and lead to degradation and recycle of ILV 
content by lysosomal hydrolases [56-58]; while others, with surface markers of late 
endosomes like tetraspanin CD63, lysosomal-associated membrane proteins (LAMP1 
and LAMP2), and MHC class II in antigen-presenting cells [59], can fuse with the 
plasma membrane and release ILVs like exosomes. By forming an inward budding 
vesicle and then releasing in the endosomal lumen of the membrane vesicle with a small 
portion of cytosol, the ILVs are able to segregate cargo at the endosomal membrane. 




in at least two known mechanisms, one depends on the endosomal sorting complex 
required for endosomal sorting complex required for transport (ESCRT) and/or 
ubiquitin machinery, whereas the other is ESCRT-independent. 
Exosomes contain many ubiquitinated proteins and they are incorporated with 
MVBs sorting pathway and ESCRTs [60]. ESCRT is highly a conserved protein from 
yeast to mammals [61] and it is composed of four different complexes (ESCRT-0, -I, -
II and -III) with several associated proteins (VPS4, VTA1 and ALIX) [62, 63]. ESCRT-
0, ESCRT-I and ESCRT-II mostly assemble within cytoplasm while ESCRT-III and 
Vps4-Vta1 are mainly present on membranes for late processing [64] [65]. The 
ESCRT-0 complexes are the first subunits to recognize and segregate the ubiquitinated 
transmembrane proteins. A hepatocyte growth factor–regulated tyrosine kinase 
substrate (HRS) is the main component of ESCRT-0 that takes charge of the 
recognition in ubiquitinated cargo proteins. HRS also helps an alliance with the other 
ESCRT-0 components, signal transducing adaptor molecule (STAM), and other non-
ESCRT proteins, such as Eps15 and clathrin. A deficiency of HRS results in failure of 
dendritic cells to release exosome and restrain the antigen-presenting activity through 
exosomal regulation [66]. Moreover, HRS helps to recruit TSG101, a GPI-anchored 
protein, of the ESCRT-I complex and ESCRT-I will participate in the following 
recruitment of ESCRT-III via ESCRT-II or ALIX. The ESCRT-I and -II complexes are 
able to help membrane deformation into buds with sorted cargo in endosomal 
membrane, and ESCRT-III components subsequently drive vesicle scission [61].  
Therefore, with the help of ESCRTs-I, -II, and –III, the cargoes start to accumulate on 




as Hsc70 [67] that are proposed to help the inclusion of protein cargo into ILVs. At the 
end of the sorting, an AAA-type ATPase, VPS4, will disrupt the ESCRT complexes 
and the inward membrane with its accumulated cargo forms the MVBs. Most of the 
cargoes in MVBs are destined for degradation. For example, the majority of the 
ubiquitinated protein like epithelial growth factor (EGF) receptors, c-Met, and gp130 
will be degraded by lysosomal proteases. However, some ILVs in MVBs will release 
as exosomes by direct fusion with the plasma membrane. Here, the Rab GTPases 
members, Rab5, Rab11, Rab27a and Rab27b, play an essential role in formation and 
secretion of exosomes [68]. 
However, ILVs are still able to form in the absence of ESCRTs. When applying 
siRNA oligonucleotides against HRS, Tsg101, Vps22 and Vps24 to abolish the key 
subunits of ESCRTs family, ILVs are still produced. As a result, other means of 
generating ILVs must exist, while the ESCRTs are still required for the biogenesis of 
growth factor-induced MVEs [65]. 
The mechanisms for their generation are less clear. Normally, the proteins sorting 
into exosomes are through ESCRT machinery, whereas generation of the ESCRT-
independent cargoes, like tetraspanin CD63, is dependent on ceramide instead of HRS. 
In Jurkat T cells, CD 63 is a protein abundant on ILVs but with unclear function, and 
it can lead to secretion and sorting of ILVs and therefore exosome through the 
ceramide-dependent pathway [69]. Another example of the ESERT-independent 
pathway is MAL, a tetraspanin membrane protein which is a critical element in 
constitutive exosome secretion in Jurkat T cells. In the absence of MAL, the exosome 




HIV-1 Nef protein induction, which is known to induce exosomal markers 
accumulation in exosome [70]. Furthermore, phospholipase D2 (PLD2), activity in rat 
basophilic leukemia 2H3 cells is correlated with the amount of exosome released upon 
stimulation [71]. Other research indicates that the ESCRT-independent pathway may 
be facilitated by lipids such as ceramide, and lipid metabolism enzymes like neutral 
sphingomyelinase (nSMase) since the blockade of nSMase 2 will inhibit the exosome 
production [69].  
Moreover, the certain selective ways to sort the various exosomal cargoes can 
reflect its original cell properties while further details still need to be confirmed. For 
example, Jurkat T cells activated by anti-CD3 will release exosomes contained T cell 
receptor subunit and adhesion molecular which are commonly found in normal T cells 
[72]. Also, exosomes derived from APC have similar properties as APC which could 
directly influence the naïve T cells through the MHC/peptide complex and the 
costimulatory molecules on the surface [59]. Not only certain molecules are thought as 
specifically found in cell-type of exosomes, the detailed sorting mechanism in various 
cells have also been proposed. For example, the co-stimulatory molecule CD86 and 
several tetraspan proteins, such as CD53, CD63, CD81, and CD82 are selectively 
enriched in exosomes secreted by B-cell. [73] In CD81 deficient mice, the secreted 
exosomal content had diminished tetraspanin CD-81 associated proteins like CD20, 
ICAM and B-cell receptor. Mittelbrunn and his team have shown that miRNAs are 
selectively delivered from active T cell to APC via exosome on immune synapsis by 
ceramide-dependent secretion [55]. Further research has indicated that the exchange of 




immunological synapse. Furthermore, recent findings are focusing on the novel sorting 
mechanism and packing system of the exosome and it will help to illuminate the 
importance of exosome.  
 
Characterization of Exosome 
Electron microscopy is mainly used for characterizing the exosomes and exosome 
marker proteins are another important means to identify exosomes [74]. Due to their 
endosomal origin, most exosomes are enriched in proteins associated with the 
specialized membranes transport and fusion such as Rab-family GTPases, Annexins 
and flotillin-1. Tetraspanin molecules (CD63, CD9, CD81 and CD82) are commonly 
used as protein markers of exosomes. They can regulate the internalization and sorting 
of proteins towards exosomes [75] For example, Alix and TSG101 are endosomal 
sorting proteins required for transport (ESCRT)-associated proteins and involve in 
multivesicular body biogenesis. Other common exosomal cargos include major 
histocompatibility complex (MHC I and MHC II), heat shock proteins (Hsc70, Hsp 
90), adhesion molecules, as well as lipid-related proteins and phospholipases. The 
major proteins in exosomal content are cytoskeletal, ribosome and mRNA granule 
proteins which help the biogenesis of exosomes. Also, lipids such as cholesterol, 
sphingomyelin, ceramide and ganglioside GM3 are routinely found in exosome content 
due to their origins. Some of them will concentrate especially in the membrane to form 
membrane rafts [76]. Moreover, activated CTLs expressed typical exosomal markers 




Although scientists heavily rely on these exosomal marker proteins to confirm the 
presence of exosomes, the complexity of cell type-specific proteins makes us cannot 
always find the markers in exosomes and unexpected cargoes may be present in the 
exosomes [77]. Moreover, proteomic analysis has shown that majority of the exosome 
are the same while few are selectively enriched under the diverse circumstance. For 
example, activated CTLs expressed massive proteins which their functions were 
relative to related to nucleic acid binding and enzyme modulators [50]. The selective 
proteins only specific to certain cell type under particular environment will determine 
the biological functions of exosomes. Overall information about protein and RNA 
being identified in exosomes has been reported to the database and open to access [77, 
78] 
 
     Current findings and applications of exosome 
The increasing focus on exosome has exploded due to their aid in 
communication among cells. First of all, several studies have found unexpected cargo 
in exosomes. For example, mRNA was found in secreted exosomes by Glioblastoma 
tumor cells and it delivers the genetic information to the recipient cell [79]. In 
embryonic stem cells, mRNA and several transcription factors are selectively enriched 
in secreted extracellular vesicles and they could be transferred into recipient 
hematopoietic progenitor cells and translated to corresponding proteins [80, 81]. Small 
non-coding RNAs, like microRNA, are also found in exosomes from mast cells [82]. 
Hence, exosomes are linked with cell-to-cell signaling, including antigen presentation, 




cargoes inside the bilayer lipid membrane while circulating in body fluid. This makes 
exosomal cargoes impervious to circulating nucleases [83] and proteases and avoid 
being attacked by the immune system by digestion of phagocytes because exosomes 
are usually recognized as ‘self’. The small-sized structure of exosomes also enables 
them to pass through a certain barrier, such as the blood-brain barrier, in our body 
effortlessly. More importantly, CTLs stimulated by IL-12 have been shown to secret 
bio-functional exosome to facilitate the communication between activated CTLs and 
naïve CTLs [50]. It was the first report that CTLs stimulated by three signal model 
could deliver messages to bystander-CTLs and enhanced the T cell activation through 
secretion of exosomes [50].   
Taken altogether, exosomes can transport and deliver cargoes enclosing 
sophisticated functional molecules to neighboring cells or even distinct receptor cells. 
The exosomal cargos can be taken up by direct fusion with cells and they subsequently 
affect recipient cells. The discovery of their function in the exchange between cells has 
brought increasing attention to exosomes because they are considered as an effective 
regulator and intercellular communication.  
Exosomes not only become a way for intercellular communication but also 
become a useful tool for the diagnostic purposes because their cargoes suggest the 
nature of the original cells [84]. Since we already know that the exosome secretion will 
be altered during the infection, the components inside the exosome will provide us a 
hint about the status of the cell cycle and the important information regarding an 
infection process. Besides, exosomes are extensively present in almost all biological 




approaches for detecting and diagnosing the disease with greater speed and lower cost 
of analysis. Take glioblastoma-derived exosomes for an example; they carry a 
diagnostic set of mRNAs (EGFRvIII) in the serum of glioblastoma patients and this is 
a potential for brain tumor diagnosis [54] In addition, recent studies have shown that 
cancer patients exhibit different patterns of RNA and miRNA. Total 8 microRNAs 
(miR-21, miR-141, miR- 200a, miR-200c, miR-200b, miR-203, miR-205 and miR-
214) were compared in exosomes isolated from various stages of ovarian cancer and 
played significantly distinct profiles from that observed in the benign disease. 
Therefore, miRNA from circulating tumor exosomes are proposed as promising 
diagnostic markers for detection of ovarian cancer, extending its utility to screening 
asymptomatic populations [85]. Taken all, exosomes are the new promising approach 
to detect and diagnose many diseases, including imperceptible cancer.  
Lastly, exosomes are a potential means of drug discovery [86]. With the ability 
to package and deliver active drugs, exosomes derived from mesenchymal stromal cells 
can be exploited to selectively deliver therapeutic genes or drugs to tumors [87]. By 
using immature DCs derived from the bone marrow of mouse as a source of exosomes, 
scientists tested the possibility of loading exosome with the MAGE tumor antigens( 
MAGE-A3, -A4, -A10, and MAGE-3DPO4 peptides) in patients with non-small cell 
lung cancer (NSCLC) as a safe, feasible and efficient drug delivery system [88]. 
Exosomes also have the ability to concentrate and sequester different antitumor drugs 
to overcome drug-resistance, which is a key determinant of cancer chemotherapy 
failure. For example, cancer cell resistance to drugs and antibodies are linked with an 




exosomes regulated by ABCA3 can carry CD20 to shield target cells from antibody 
attack, and both pharmacological blockade and the silencing of ABCA3 enhanced 
susceptibility of target cells to antibody-mediated lysis [89, 90]. Moreover, since many 
tumor antigens, such as carcinoembryonic antigen (CEA) and mesothelin, are found in 
tumor-derived exosomes, many studies have proposed the promising development of 
tumor exosome-based cancer vaccines. For example, Hsp70-enriched exosomes from 
heat-treated tumor cells can increase immune stimulating activities and Th1 typed anti-
tumor effects in both autologous and allogeneic mouse models. This could be a novel 
MHC cancer vaccine providing tumor antigenic [91]. 
To conclude, exosomes have drawn significant attention since they help the 
transporting of functional molecules for communication, diagnosis and disease 
treatment. Also, like the previous statement, many types of research have indicated that 
exosomes are present in almost all biological fluid, such as plasma, urine, breast milk. 
The extensive presence of exosomes can contribute because they are secreted by many 
somatic cells, including epithelial cells, immune cells and tumor cells. Among them, 
immune cells release considerable exosomes into the mammalian fluid, and therefore 
they are thought as a critical role in immunity.  
 
The important role of the exosome in immunity and CTLs 
Exosomes have significant roles in immune responses and several immune cells 
secrete functional exosomes, under both normal and stimulated environment. B cells, 
dendritic cells and mast cells of the immune system appear to not only release 




the intercellular interactions. For example, murine dendritic cells, which can activate T 
lymphocytes, secrete higher levels of exosomes upon engagement with antigen-specific 
CD4+ T lymphocytes and can promote anti-tumor immune responses in mice. Tumor 
peptide pulsed DCs-derived exosomes, which expressed MHC class I, suppressed 
tumor growth in the tumor bearing mice and further mediated specific cytotoxic T 
lymphocytes activities. This suggests that DC-derived exosomes play a potential role 
in cancer immunotherapy as a novel therapeutic cancer vaccine and indicate that 
exosomes can communicate to T lymphocytes [92]. Exosome-like vesicles released by 
melanoma cells bears FasL and help the tumor to escape and hinder the anti-tumor 
activity of lymphocytes[93]. Human B cells and T cells release more exosomes upon 
interaction with antigen-specific CD4+ T cells and antigen receptors, respectively [94]. 
Lastly, activated T cells released great amounts of exosomes during activation[95, 96].  
In addition, exosomes from APC have been suggested to promote antigen 
recognition; CD4+ T cells have been demonstrated to deliver activation signals [97]. 
Other research showed it cannot find the exosome in the supernatant stimulate with 
PMA with ionomycin, which is known to induce NF-AT activation and IL-2 
production. This indicated that the production of exosome may be specific to TCR 
activation. Therefore, exosomes bearing TCR/CD3 complexes at surface had the 
potential to specifically trigger the target human T cell activation through MHC I/TCR 
complex [72] Furthermore, exosomes directly loaded with OVA323-339 peptide 
induced stronger T-cell proliferation both in vivo and in vitro, and stimulate OVA-
specific Th1 response in mice [98]. Exosomes derived from B cells can also assist 




function [99]. Many findings have revealed that exosomes are potent immune 
regulators and are relevant for the development of a therapeutic treatment to modulate 
immune responses, especially in T cells. 
However, little is known about how exosomes mediate T cell function through 
cell-to-cell communication. The previous studies mainly focus on exosomes secreted 
by APC that can induce T cell response. Now, more and more research has discovered 
the T cell autologous activation through exosomes. Exosomes originating from 
activated CD3+ T cells together with IL-2 were able to generate proliferation in 
autologous resting CD3+ T cells and have the higher proportion of CTLs and alter the 
cytokine profile. This indicated the intercellular communication between activated and 
resting T cell through exosome to prevent the tolerance state and enhance the T cell 
activation [100]. Activated human T cells upon PHA stimulation can release exosomes 
containing bioactive Fas ligands (FasL) and APO2 ligands which subsequently induce 
self-apoptosis of T cells to prevent the autoimmune disease [96]. Further research 
showed that this secreting exosome will improve tumor expansion and damage the 
CTLs antitumor activity in a FasL-dependent way [101]. In addition, exosomes derived 
from antigen-specific T cells suppressed CTL cytotoxic responses and antitumor 
immunity[102]. Lastly, as mentioned before, activated CTLs triggered the bystander 
activation in the resting CTLs without the presence of antigen [50] and the exosomes 
enhanced and helped to maintain the CTL immune response. This confirmed the critical 
role of exosomes in enhancing the communication between activated CTLs and weak 




exosomes derived from T cells can serve as tumor treatment and improve T cell 
function in the future. 
As a result, we hypothesized that exosomes derived from CTLs stimulated by 
3 signals model (3SI) using highest-affinity peptide will enhance the activation of low-
affinity CTLs. We would like to investigate the function of Exo in activating CTLs 
with low-affinity. Also, since CTLs stimulated by 3 signals model have shown to secret 
bio-functional Exo in the late stage of activation [50], we would also identify whether 





Chapter 2: Materials and Methods 
Experiment Scheme 








Figure 1. Experimental scheme. Naïve CD8+ T cells were purified from OT-1 
transgenic mice through negative selection. After one-day and three-day stimulation 
of 3SI, exosomes (Exo) were purified from the supernatant (exosomes purified from 
day one, D1 Exo; exosomes purified from day three, D3). The purified Exo was 
characterized by their morphology and protein expression. In addition, naïve CTLs 
were stimulated by peptides with/without Exo. All activated CTLs were stained with 




Purification of naïve T cell 
The mice were euthanized, and peripheral lymph nodes were collected. The 
harvested lymph nodes were homogenized in 15 ml glass grinders in Allos medium. 
After washing with Allos several times and filtering with 0.75uM nylon filter, the cells 
are incubated together with FITC-labeled antibodies that are specific for B220, CD4, 
CD44, CD11c and I-Ab for negative selection. The suspension was subsequently 
incubated with FITC binding magnetic MicroBeads (Miltenyi Biotech, Auburn CA), 
and pass through separation columns attached to a MACS magnet. Cells that do not 
bind to the column were collected and use FACS to confirm the purity (>95% CD8+ 
and <0.5% CD44hi cells).  
 
Activation of naïve CTLs 
Purified naïve T cells are stimulated in vitro with Allos in 48 wells flat-bottom 
microtiter wells coating with antigen (peptide A) (DimerX H-2Kb: Ig fusion protein 
loaded with OVA257-264 peptide; BD Pharmingen), recombinant B7-1/Fc chimeric 
protein (R&D Systems) and 2U/ml of murine rIL-12 (R&D Systems) as previously 
described [50, 103]. 3 × 105 cells in 1.5 ml Allos media are placed in each well and 
2.5U/ml IL-2 added to all wells. Treatment without IL-12 will serve as control. In 
affinity test, purified naïve T cells are treated with different affinity peptides A, B, C, 
D, E, F with or without exosomes stimulation. The peptides are different in affinity 





Purification of exosomes 
Exosome free medium was generated by centrifugation at 100,000 g for overnight 
and supplemented with 10% FBS. Naïve T cells were seeded and incubated for day1 
and day 3, we harvested the cell supernatants for exosome purification by several steps 
of centrifugation and filtration [50]. Briefly, cells were centrifuged at 300g for 5min 
followed by 10,000g for another 10 min to remove the debris. The supernatant was 
collected to filter through 0.22 μM membranes. After, exosomes were precipitated by 
PEG for overnight and are pelleted by ultracentrifugation at 100,000 g for 90 min at 
4°C (Beckmen XL-90, Beckman Coulter). Purified exosomes were determined for 
protein concentration by Bradford microassay method (BioRad Laboratories) and safe 
in -80°C for following use. Size distribution of in vitro T cell-derived exosomes from 
various time points were estimated by Malvern Zetasizer Nano ZS90 (Malvern, UK). 
 
Nanoparticle tracking analysis and transmission electron microscopy 
The presence and concentration of exosomes from activated T cells were 
determined by using a nanoparticle tracking analysis (NTA) and transmission electron 
microscopy (TEM). NTA was carried out by using the NanoSight LM10 on purified 
exosomes which were diluted 20-fold in 400ul PBS. After loading into NanoSight 
chamber, data of each sample will be collected from different views and analyzed by 
NTA2.1 software. Exosomes containing 0.03–0.3 pg protein will suspend in 2% 
glutaraldehyde and apply to a Formvar-coated grid and negatively stained with uranyl 




microscope at an accelerating voltage of 80keV26. Exosomes validated by protein 
markers and electron microscopy will be further used for the following experiments.  
 
Western Bolt  
Protein (10μg) extracted from purified exosomes were separated by 
electrophoresis on 10% SDS-polyacrylamide gel and analyzed by western blotting. 
First, the protein was transferred to a Polyvinylidene Difluoride (PVDF) membrane 
(BioRad, Hercules, CA) and blocked with a 20 mM Tris-HCl, pH 7.6, 150 mM NaCl, 
and 0.05% Tween-20 blocking solution (TBST) containing 1% bovine serum albumin 
(BSA). Incubate the membrane with the first antibody at room temperature (RT) for 1h 
and wash for 3 times using TBST to remove the exceed antibody. Following incubation 
of the membrane use horseradish peroxidase (HRP)-conjugated anti-bovine IgG 
secondary antibody for 1h at RT. Signals were detected by the SuperSignal West Pico 
Chemiluminescent Substrate and a Gel Doc imaging system. 
 
Cell proliferation 
The purified naïve T cells were washed in HBSS, resuspended in HBSS (1 x 107 
cells/ml) containing carboxy-fluorescein diacetate succinimidyl diester (CFSE) at a 
final concentration of 0.5 µM. Incubated for 5 minutes at 37°C and transferred to cold 
Allos medium. Subsequently cells were washed twice times with Allos medium and 






Cell staining and T cell activation analysis 
Naive CD8+ T cells are stimulated by exosome isolated from day1 and day 3, 
respectively. The quantity and quality of CD8+ T cells activation will be determined 
by flow cytometry (BD Biosciences) and analyzed using the FlowJo software. T cell 
activation markers and production of functional molecules, such as CD25 and CD69 
expression IFN-γ, TNF-α, and granzyme B will be examined to determine the 
activation process. CD25 and CD69 will use the normal surface according to protocol 
and intracellular staining will be used for IFN-γ, TNF-α, and granzyme B secretion 
analysis. Particularly, IFNγ expression will be induced by incubating in RP-10 with 0.2 
μM OVA257–264 peptide and 1 μL Brefeldin A (BioLegend) for 3.5 hrs at 37°C. After 
peptide and BFA stimulation, cells are stained based on protocol. Briefly, we add 4% 
Fixing buffer to the cells at one to one ration for 15 minutes at 4°C, after the cells are 
permeabilized in Saponin-containing Perm/Wash buffer (Biolegend) for another 15 
minutes at 4°C, then stained with color-conjugated antibody for 30 minutes at 4°C. 
Finally, the cells are washed once with Perm/Wash buffer and Resuspend in 2% FBS 
Staining buffer. The analysis will be done using a FACS Diva flow cytometer and 
FlowJo software. Finally, to further test the optimal activation of T cell, the exosomes 






Chapter 3: Results 
Exosomes enhanced cell proliferation in low affinity peptide treatment 
Robust cell proliferation takes place after CTL activation in response to antigen 
stimulation. Generally, T cells with high affinity had increasing cell proliferation [104]. 
Although T cells with low affinity may initiate the same proliferative rate as T cells 
with high affinity, it showed limited expansion during the in vivo response to microbial 
infection [30]. However, their study was done in the different system where naive CTLs 
derived from OT-1 mice were grafted into B6 wild-type mice and various peptides were 
presented by recombinant Listeria monocytogenes. Therefore, more factors are 
introduced in the systems while we were only focusing on the difference of peptide 
affinity. Because peptide/TCR affinity is the main factor contributed to immerse CTLs 
response to antigen stimulation [26], we first tested the effects of various affinity 
peptide treatment on cell proliferation. CFSE is often used for tracking of multiple 
generations during proliferation through dye dilution analyzed by FACS [105, 106]. 
After purification, CTLs were labeled with CFSE to track the cell generation through 
dye dilution analyzed by FACS [105]. CFSE-labeled CD8+ T cells were stimulated by 
peptides with the diverse affinity (peptide A, B, C, D, E, F, respectively) only and co-
stimulators. With diluted CFSE signals indicating cell division, CD8+ T cells treated 
with higher and intermediate-affinity peptides (peptides A, B, and C) underwent similar 
rounds of cell cycles after 48-hour stimulation. Low-affinity peptide stimulation 
(peptides D, E, and F) had fewer cells entering the cell cycle with most of the cells 




the proliferation of CTLs was dependent on the peptide/TCR affinity. Since in Zehn’s 
study, the low-affinity peptides stimulation could lead to the similar rate of proliferation 
compared with high-affinity peptides stimulation at the initial stage of infection [30], 
we speculated that endogenous T cells may respond to peptides and help the activation 
of low-affinity CTLs from TCR transgenic mice.  
Next, we purified the exosomes from the vesicle-depleted supernatant of fully 
activated CTLs treated with the highest-affinity peptide (peptide A), co-stimulators 
(IL-2, Dimer X and B7) and IL-12 after three days of stimulation (D3 Exo) [50]. The 
purified D3 Exo together with the peptides of various affinities were added in vitro to 
stimulate the CFSE labeled CD8+ T cells. We examined the percentages of divided 
CTLs in the same round of the cell divisions based on their diluted CFSE intensity (UD, 
D1, D2, D3) and compared the exosome treatment with the control. In the groups of 
high to intermediate-affinity peptides (peptide A, B, and C), the treatments with the 
peptide and the D3 Exo showed most of the cells had divided three times, similar to 
cells in the peptide only control. However, in the group of low-affinity peptides, D3 
Exo pushed more cells into cell cycle progression, especially in peptides E and F. And, 
for those dividing cells, D3 Exo enhanced more cells to enter division 3 in peptide E, 
and division 2 in peptide F (Fig. 2B). Therefore, the D3 Exo enhances the proliferation 
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Figure 2. Exosomes increased the cell proliferation in low-affinity peptide treatment. 
Purified naïve CD8+ T cells were first labeled with CFSE and stimulated with 
peptides in the presence or absence of D3 Exo to monitor cell division by diluted 
fluorescent signals.  The peptides were ranging from high affinity (peptide A) to low 
affinity (peptide F). (A.) Cell division of in vitro activated CTLs, which were 
stimulated with peptides with diverse affinities were examined by FACS two days 
after stimulation (B.) Total cell number of each generation of divided CTLs was 
analyzed in the control (peptide only, black lines) and the treatment with peptides 
and D3 Exo (Red lines). (ND: undivided cells; D1: cells entering first division cycle; 





 Exosomes increased the survival of CTLs treated with low-affinity peptides 
To sustain the CTL population during an immune response, the number of CTLs 
can be affected by either rate of proliferation or ability to survive, or both [107]. We 
had demonstrated that exosomes stimulated the proliferative rate in the treatments with 
lower-affinity peptides during the two-day expansion (Fig. 2B). We wonder whether 
these D3 Exo affected the total number of cells through the involvement of difference 
in survival.  
When we compared the D3 Exo treatment with the control, which was treated 
with peptide only, D3 Exo enhanced cell number in every peptide treatment, by 1-2 
fold between A to D. However, the increase was raised to 4-8 folds in low-affinity 
peptides E and F (Fig.3A). There was no difference observed in CFSE dilution in 
peptides A-C in the presence of D3 Exo, suggesting that D3 Exo positively influence 
the survival in CTLs stimulated in high to intermediate peptides. Despite the fact that 
the D3 Exo pushed more cells into cell cycle, and furthered cell cycle progression 
(Fig.2B), the increase of cell number by D3 Exo in peptides E and F, was much bigger 
than the effects explained by the difference in proliferation rate driven by D3 Exo, 
indicating D3 Exo may enhance the cell survival in CTLs treated with low-affinity 
peptides, possibly to an extent bigger than high to intermediate peptides (Fig.2B and 
Fig.3A). IL-2 plays a major role in providing survival signal to T cells, through 
triggering IL-2 signaling upon ligating with a IL-2 receptor. CD25 is the alpha subunit 
of IL-2 receptor, which is upregulated once T cells are activated, which enhances the 
IL-2 signaling to facilitate T cell survival. To test if D3 Exo enhances peptide-




expression in each dividing cycle in each peptide treatment. Indeed, the presence of D3 
Exo enhanced CD25 expression in cells in every cell cycle, from undivided, to cells in 
division 3 (Fig.3B), and these effects of D3 Exo were observed similarly in all peptide 
stimulation (data not shown). Therefore, D3 Exo can enhance the proliferation and 
survival of peptide-stimulated CTLs, preferentially with low affinity-peptides. And, the 
survival effects could be contributed by enhanced IL-2 signaling by D3 Exo, which 
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Figure 3. D3 Exo enhanced the survival of CTLs treated with low-affinity peptides 
by upregulating CD25. Naïve CD8+ T cells were stimulated with peptides in the 
presence or absence of D3 Exo. (A.) Cell expansion affected by D3 Exo. Data were 
expressed as the ratio of cells number of (D3 Exo+ peptide) divided by peptide only 
control, following two-day and three-day stimulation (D2 and D3). (B.) The 
expression of CD25 in each division (indicated by CFSE dilution) of CTLs treated 
with exosome was compared with CTLs treated without exosome (UD: undivided; 





Exosomes stimulated the generation of IFN-γ in low-affinity CTLs 
After antigen stimulation, CTLs initiate the cell proliferation and the 
development of CTL effector function [108]. CTLs must receive comprehensive 
activation signals including cytokine to develop the effector function [16, 109]. To 
understand the effects of exosomes on the development of CTL effector function, we 
test the production of effector cytokine, IFN-γ [110].  
Our results showed that although encountering with high-affinity peptide, the 
stimulation of peptide only could only induce the cell division (Fig. 2A) while failed to 
produce IFN-γ (Fig. 4A). Surprisingly, the treatment of the D3 Exo overcame the 
disadvantages of low-affinity peptide stimulation and induce the production of IFN-γ. 
Like the results of CTL expansion, the D3 Exo enhanced IFN-γ production mostly in 
CTLs stimulated with low-affinity peptides instead of high-affinity peptides (Fig. 4A). 
Moreover, we analyzed the relationship between IFN-γ production and cell 
generations. We found that the effects of the D3 Exo stimulation to induce IFN-γ 
production were significant in the later rounds of cell division (Fig. 4B).  
In summary, CTLs stimulated by high-affinity peptide failed to generate the 
IFN-γ in all cell generations.  However, the exosome promoted the IFN-γ production 































Figure 4. D3 Exo treatment induced IFN-γ production. Naïve CTLs were labeled 
with CFSE and stimulated peptide, and with/ without the D3 Exo for three days (A) 
or two days (B). Cells were harvested and stimulated with the corresponding 
peptide for 3.5 hrs. The cells were then stained for intracellular IFN-γ. (A.) IFN-γ 
expression on activated CTLs (B.) IFN-γ production and cell generation of 
activated CTLs was compared between the treatment of the peptide E (E) and the 




Low-affinity CTLs stimulated with exosomes exhibit higher GZB, corresponding to 
CD25 
Production of GZB which responsible for the cytotoxic activity of CTLs is 
another major effector molecule [1, 110]. Since CTLs must receive comprehensive 
signals to develop the CTL effector function [111], different peptide affinity did not 
significantly contribute to the induction of IFN-γ (Fig. 4A). The previous study showed 
that in vivo stimulation of CTLs by microbial did not result in the significant difference 
between high-affinity peptide treatment and low-affinity peptide treatment[30]. 
However, we demonstrated that stimulation of low-affinity peptides, not high-affinity 
peptides, led to induction of GZB (Fig.5A). To validate the effects of low-affinity 
peptides on the effector function of CTL, we tested the T cell activation marker, CD25. 
The expression of CD25 was upregulated when treated with low-affinity peptides (Fig. 
5A).  
Based on our results, the stimulation of high-affinity peptide can trigger the cell 
proliferation (Fig. 2A) while fail to induce the effector function (Fig. 4A and 5A). In 
contrast, the stimulation of low-affinity peptide showed limited cell proliferation (Fig. 
2A) while promoted the development of effector CTLs, with enhanced survival rate 
(Fig. 3A), IFN-γ production (Fig. 4A) and higher expression of GZB and CD25 (Fig. 
5A).  
After observing the strong correlation between GZB production and CD25 
expression (Fig. 5A), we tested the role of exosomes in activating low-affinity CTLs. 
When treated with the D3 Exo and the peptide, CTLs produced more GZB than the 




expressed higher CD25 (Fig. 5C). Thus, exosomes enhanced GZB production in all 




















































































Figure 5. Exosomes increased the production of GZB, which was corresponding to 
CD25 expression, in the treatments of low-affinity peptides. Naïve CTLs were 
stimulated with different peptides for three days and stained for expression level. 
The expression of intracellular GZB and surface CD25 was obtained by FASC based 
on fluorescent intensity. (A.) The GZB and CD25 expression in response to the 
treatment of peptides with diverse affinities. (B.) The production of GZB and (C.) 





Activated CTLs secreted exosomes since the early stage of activation 
To induce the maximum immune responses, the effects of the exosome i.e. 
bystander activation of naïve CTLs and stimulation of low-affinity CTLs should take 
place as early as possible. In addition, cells, especially immune cells, are reported to 
continuously generate the exosomes during infection [112]. Therefore, we investigated 
the weather early activated CTLs could generate exosomes as a short-term response to 
infection.  
We isolated the two populations of exosomes from an early stage and a late 
stage of activation. First of all, purified naïve CD8+ T cells from OT-I mice were fully 
activated with antigen and co-stimulators plus IL-12 in vesicle-depleted media [50]. 
The supernatant was collected from one day or three days following stimulation to 
purified extracellular vesicles. The purified extracellular vesicles displayed round 
shape structure with a double layer using TEM (Fig.6A). The protein yield was 
obtained by total protein concentration divided by total collected supernatant. D3 Exo 
yielded protein as 2.23 μg/ml. Surprisingly, the D1 Exo yielded abundant protein (0.9 
μg/ml) considering that CTLs only started few cell proliferation (only 1/10 cell 
numbers compared with D3 CTL) at D1(Fig. 6A). The vesicles derived from CTLs 
stimulated for one day (D1 Exo) were smaller than three days stimulation of CTLs 
derived vesicles (D3 Exo), with mean sizes of 30.25 nm and 45.62 nm, respectively, as 
detected by a Nano ZS90 (Fig. 6A). The vesicles demonstrated size ranges and 
morphology consistent with exosomes [50, 57]. As a result, we confirmed that the 
extracellular vesicles from activated CTLs with one day or three days stimulation was 




Next, we tested whether vesicles derived from CTLs of one-day stimulation 
expressed typical exosome markers [75]. Equal amounts of protein from purified 
vesicles and activated CTL lysates were examined by western blot. Although we there 
is no exclusive house housekeeping genes for EVs (exosomes and microvesicles) 
currently, we chose the most widely used one as the reference gene, β-actin. Both the 
D1 Exo and the D3 Exo contained comparable amounts of β-actin (Fig. 6B). Even 
though D3 Exo displayed the selective enrichment of exosomal proteins like Flotillin, 
Tsg101, and Alix, D1 Exo expressed extreme low (Flotillin and Alix), or even not 
detectable (Tsg101) exosomal markers (Fig. 6B).  
Overall, the D3 Exo was larger and more enrich with exosomal markers, CTLs 
activation signal (Zap70), and effector molecular (GZB) than the D1 Exo. The results 
indicated that D1 Exo was smaller and only expressed limited protein expression. Also, 
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Figure 6. Activated CTL-derived vesicles in the early stage of activation expressed 
typical exosome morphology and protein markers. Naïve CD8+ T cells purified 
from OT-I mice were in vitro activated by peptide A, B7, IL-2 and IL-12 for one 
day and three days. The extracellular vesicles were purified from each supernatant 
and characterized. Each experiment was replicated at least three times with similar 
results. (A.) Purified vesicles were observed under Zeiss EM10 transmission 
electron microscope. The graphs vary on amplification magnitude, and the bar in 
each graph indicates 50 nm. Size distribution of D1 Exo and D3 Exo measured by 
Malvern Zetasizer Nano ZS90. Protein yield was measured by total protein 
concentration/ supernatant (μg/ml). (B.) Representative blots showed exosome 
markers and CTL-associated protein. Purified exosomes from one day (D1 Exo) 
and three days (D3 Exo) activated CTLs were loaded at 10 μg protein in each lane 




Early secreted exosomes triggered bystander activation in naive CTLs  
In the previous report, we had discovered that D3 Exo derived fully activated 
CTLs can induce the bystander activation in naïve CTLs [50]. We would like to know 
whether the early secreted exosomes have the same function of inducing bystander 
activation like late secreted exosomes.  
Purified D1 Exo and D3 Exo were added to the culture media supplied with IL-
2 to stimulate naïve CTLs. The CTLs were harvested after three-day culture and stained 
with the corresponding antibody. Based on the dilution of CFSE dye, The CTLs were 
divided into CFSE- as cells entering the cell cycle or CFSE+ group as undivided cells. 
The percentage of CTLs entering the cell cycle was 3.74% in the group of the D1 Exo 
while it was 4.68% in the group of the D3 Exo (7A). Exo drove bystander-CTLs 
proliferation and dividing while D3 Exo was stronger than D1 Exo.  
We next investigated the common used CTLs activation markers, CD25 and 
CD69, using FASC since activated CTLs expressed increasing CD25 phenotype [113] 
. We found out that the expression of CD25 was increased in both D1 Exo (67.3%) and 
D3 Exo (72%) and CD69 was also enhanced in D1 Exo (69.3%) and D3 Exo (69.2%) 
(Fig. 7B). We also observed the strong enhancement of GZB (13.3% in D1 Exo and 
23.5% in D3 Exo) and IFN-γ production GZB (46.3% in D1 Exo and 62.9% in D3 Exo) 
(Fig. 7B). In short, D1 Exo had very similar but somewhat weaker effects to induce the 
expression of activation markers and effector molecules. CFSE+ expressed little 
enhancement in the expression of activation markers and effector molecules (Fig. 7B). 
Together, exosomes derived from an early stage of CTLs activation was sufficient to 
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Figure 7. D1 Exo and D3 Exo induced the bystander activation in naïve CTLs. 
Exosomes were purified from the supernatant of one-day and three-day stimulated 
CTLs (D1 Exo and D3 Exo). Exo was added to the culture media supplied with IL-
2 to stimulate naïve CTLs. The expression of the cytolytic and activation related 
molecules were assessed using FACS three days after exosomal stimulation. (A.) 
Cell proliferation of CTLs labeled by CFSE. CTLs were termed as CFSE positive 
(CFSE +) or negative (CFSE -) based on the CFSE signal. (B) Expression of CFSE, 
CD25, CD69; and effector molecules like GZB and IFN-γ. CTLs were stimulated 





Exosomes derived from the early activated CTLs promoted low-affinity CTL 
activation  
We had shown that the D3 Exo can stimulate the CTL enter cell division, 
especially in low-affinity peptide treatment (Fig 2B). We wonder whether D1 Exo had 
the same effects on CTLs. Purified D1 Exo and D3 Exo were incubated with CTLs 
treated with different peptides. As D3 Exo was more powerful than D1 indicating by 
previous results (Fig. 7B), exosomes helped the cell division while the D3 Exo was 
stronger in stimulating the cell dividing compared with the D1 Exo. The help was 
drastically in the low-affinity peptide treatment (Fig. 8A).  
We next investigated the expression of several CTL activation markers to 
analyze the D1 Exo function. In comparison to the peptide stimulation only, CTLs 
treated with the exosome and the peptide generally exhibited a higher level of CD25, 
IFN-γ and GZB (Fig. 8B). Also, the production of effector molecular (GZB and IFN-
γ, especially GZB) in low-affinity CTLs was significantly altered by the exosome 
stimulation which D3 Exo was stronger the D1 Exo (Fig. 8B). This was consistent with 
the previous observation that exosome had more profound and significant effects in 
low-affinity CTL than high-affinity CTL to promote the activation.  
To conclude, activated CTLs use exosome as a novel means to communicate to 
the resting CTLs since the early stage of activation. Moreover, the early-derived 
exosome can help the CTLs with low affinity to proliferate and increase the expression 















































Figure 8. D1 and D3 Exo enhanced the CTLs activation in low-affinity peptide 
treatments. Naïve CTLs were treated with diverse affinities of peptides (peptide A, 
B, C, D, E, F) with/without the stimulation of the Exo. After three-day incubation, 
the stimulated CTLs was harvested, stained with antibody cocktails and analyzed by 
FACS. (D1 Exo: day-one Exo plus peptide; D3 Exo: day-three Exo plus peptide; 
Cont: peptide only.) (A.) Cell dividing evaluated by dilution of CFSE labeling. (B.) 





Exosomes increased T-bet expression  
Finally, exosome had been reported to mediate the transcription signals during 
an immune response [114]. We investigated one of the important transcriptional 
regulators of CTL differentiation and activation, T-bet [43]. In all the treatments with 
Exo, the expression of T-bet increased while the most significant one showed in the 
treatment with low-affinity peptides (Fig. 9). In conclusion, Exo can induce the 
expression of the transcriptional regulator, T-bet, in CTLs treated with high to low-









Figure 9. D3 Exo up-regulated the T-bet expression in low-affinity peptide 
treatments. Naïve CTLs were stimulated with D3 Exo plus peptide and peptide only 
for three days. Peptides were different in affinity. Next, CTLs were harvest and 












Chapter 4: Discussion 
Since there was an indication about the strong co-relationship between the 
pMHC/TCR affinity and the magnitude of CTL expansion and function [115], many 
studies focused on identifying the highest affinity to induce CTL the response. 
Identifying the highest affinity of TCR has long been at the center of the research in 
activating CTL. For example, the goal of cancer therapy is to develop chimeric antigen 
receptor (CAR) T cells with the highest affinity to tumor cells [116, 117]. Also, CTLs 
must receive comprehensive signals to induce cell expansion and differentiate into 
effector T cells [111]. However, in the real world, CTLs cannot always contact high-
affinity peptides and receive the sufficient activation signals [103]. Actually, low-
affinity CTLs, that will only receive weak activation signals, can still sustain a 
substantial population during a CTL response and help to maintain diverse antigen 
repertoire. Without further assistance, low-affinity CTLs exhibit impaired cell 
expansion and limited function [22, 30]. More importantly, mounting evidence 
indicated that low-affinity CTLs are important to induce effector response and maintain 
a diverse memory repertoire against viral infection and cancer [39]. Therefore, to 
optimize the CTL activation and summon maximum effector response, it’s urgent to 
identify the mechanism of how signals can be delivered from activated T cells to resting 
T cells and help low-affinity CTLs to overcome the disadvantage of deficient activation 
signals. Here, we discovered that exosome stimulation improved the optimal CTL 
activation under weak stimulation (i.e. low-affinity peptide stimulation).  
To induce the appropriate immune response against intracellular infection, T 




that the weak stimulation of the antigen was sufficient to drive CD8 T cells through 
multiple rounds of division [2, 3]. This was termed as autopilot response which CTLs 
was activated due to a short-term exposure to the antigen [118]. However, the weak 
stimulation cannot induce a proper CTL cytotoxic activity against intracellular 
infection [16]. In our study, we discovered the novel mechanism to stimulate the 
activation of CTLs which was exposed to low-affinity peptides by exosomes derived 
from activated CTLs.  
The affinity between the peptide and TCR is a critical key to induce robust 
proliferation of effector CTLs against the antigen. Weak pMHC /TCR interaction can 
induce a typical exhaustion phenotype and lead to dysfunction and susceptibility of 
CTLs [119]. We showed low-affinity CTLs could overcome the disadvantages of weak 
proliferation signals by treating with exosomes and more cells entered the cell cycle 
(Fig. 2B).  
However, the cell proliferation is important while the maintenance of cell 
population is also critical to sustaining the vigorous immune response of CTLs. Antigen 
stimulation alone could lead to multiple rounds of cell division, as indicated by CFSE 
dye dilution, but cell numbers did not increase indicating impaired cell expansion 
[111]. As a result, the cell proliferation is not enough to determine the expansion of 
CTL, survival is also an important factor.  
Although high-affinity CTLs generally showed superior proliferation with more 
cell entering the cell cycle (Fig. 2B), low-affinity CTLs treated with exosomes 
exhibited significant cell expansion and maintained the cell population during 




exosome treated CTLs have better survival rate, so the total number of cell increased 
along with time. Interestingly, the treatment of D3 Exo stimulated the greatest 
expansions in peptide E, not the lowest affinity, peptide F. (Fig. 3A). This supports the 
idea that T cell expansion is not fully reliant on the peptide/TCR affinity and it is 
associated with exosomal signals. Thus, a major contribution of the exosome 
stimulation is to promote survival of the dividing cells.  
There are many factors that will affect the magnitude of CTL activation. For 
example, the cytokine is one of the key signals that regulate the immune response. We 
found that the upregulation of CD25 expression was possibly the mechanism of 
exosome to stimulate the cell division and survival in low-affinity CTLs by increasing 
the IL-2 survival signal.  
CD25 is the α chain of the IL-2 receptor [120]. IL-2 has long been considered 
as a T cell growth factor since it stimulates the proliferation and drives more T cells to 
enter the cell division cycle [121] [122]. IL-2 not only modulates the expansion of T 
lymphocytes but also can be produced by activated T lymphocytes [123]. Moreover, 
the presence of IL-2 during primary antigenic exposure is required for the development 
of effector T cells [124, 125]. Removal of IL‐2 will result in extensive cell death [126]. 
Therefore, supplying IL-2 is necessary for studying CTL activation in order to provide 
the survival signals and to mimic the inflammatory environment during an infection.  
The expression of the IL-2 receptor will be up-regulated upon CTL activation 
via TCR signaling [127].  The resting T cells express intermediate-affinity receptors to 
IL-2, IL-2Rβ/γ chains. After initiating the signal transduction trigger by pMHC/TCR 




assemble a high-affinity receptor (IL-2 α /β/γ), the α chain of the IL-2 receptor is 
essential. Similar to previous results that IL-12 is necessary to promote the cell division 
by sustaining high-affinity IL-2 signaling [129] our data showed the exosome 
stimulates the cell expansion in low-affinity CTLs by upregulation of CD25 expression 
in response to IL-2.  
We also observed that exosomes boosted the development of effector T cells by 
regulation of the CD25 expression. The upregulation of CD25 has a positive influence 
on the production of GZB in low-affinity TCRs (Fig 5A). The connection between 
CD25 and GZB was further demonstrated since the treatment of exosome stimulated 
the expression of both CD25 and GZB (Fig 5B, C).  
IFN-γ is produced by activated effector CTLs and helps to stimulate the 
immune response [17]. CTLs must be stimulated with antigen, co-stimulators and IL-
12 to obtain optimal activation [13, 15, 16], weak stimulation cannot induce the IFN-γ 
production. Therefore, the production of IFN-γ is used to recognize the CTL effector 
cells [130]. The production of IFN-γ was increased in the later rounds of cell division 
(Fig. 4B). This indicated that robust CTL expansion did not result in the development 
of effector function since peptide A treatment underwent several rounds of cell division 
while it produced low IFN-γ. Likewise, the augmentation of CD25 expression was 
more obvious in the late cell division (Fig. 3B). Upregulation of CD25 may enhance 
the IL-2 signal and lead to higher production of IFN-γ while detail mechanisms need 
further investigation.  
In short, our study indicated that the stimulation of a high-affinity peptide can 




effector function (Fig. 4A and 5A). in vivo stimulation of low-affinity peptides 
exhibited limited cell expansion of CTLs [30] while the stimulation of low-affinity 
peptides together with exosomes showed improvement of cell survival (Fig. 2A). This 
supported the theory that Exo enhanced the cell survival of CTLs. Exosome treatment 
also increased the IFN-γ production (Fig. 4A) and GZB expression (Fig. 5A). Besides, 
all the results support that the expression of CD25 might play an important role in 
activating low-affinity though IL-2 regulation. 
The prompt immune response against infection is needed to prevent the disease. 
The exosomes derived from the late stage of CTL activation has substantial effects on 
provoking the bystander activation of naïve CTLs [50] while we also showed early-
secreted exosomes also have the function. 
The contents of exosomes reflect the status of original cells. Cells may adopt 
various ways to sort and generate exosomes in responding to a diverse environment. 
Through examining the morphology of exosomes, a suggestion will be revealed about 
the way that the cells respond to stimulation and explain the intracellular changes. The 
differences in size and morphology of secreted exosomes suggests that the stimulation 
time may direct exosome formation and content. Although both one-day stimulation 
and three-day stimulation can induce the production of abundant exosomes in CTLs, 
the size and the specific type of proteins differ noticeably between D1 Exo and E3 Exo 
(Fig. 6B). D1 Exo had the similar but weaker capability to induce the bystander 
activation of naive CTLs. When encountering the infection, T cells must respond timely 




efficient communication between activated and resting T cells as a timely response to 
pathogens.  
Secondly, considering that one-day stimulation only resulted in slow cell 
proliferation and three-day stimulation resulted in significant total cell number 
increase, the one-day simulation yielded abundant exosomes based on the protein 
concentration (Fig. 6A).  Also, there were no available exosomal markers currently due 
to the specificity of cell type and distinct environment of stimulation. The markers we 
used were previously reported in the D3 Exo while other markers should also be tested. 
The production of exosomes can generally be divided into two pathways, ESCRT-
independent and ESCRT-dependent [65]. Tsg101 and Alix are the major components 
of ESCRT pathway [64]. Lacking the expression of these proteins (Fig. 6B) suggested 
D1 Exo might take other pathways to generate exosomes, as a prompt response to the 
antigen, whereas D3 Exo formation in CTLs is ESCRT-dependent. However, further 
experiments are needed to understand the mechanism of secreting Exo by activated 
CTLs.  
Flotillin is the common marker extracellular vesicle that abounds on the 
membrane [131]. The various expression in D1 Exo could be due to a bench difference 
and purification condition so more replica and more accurate assay should be adopted. 
The stable expression of activation-relative markers, Zap70, in D1 and D3 Exo 
indicated that the exosomes carried the downstream TCR signal molecule. Moreover, 
exosomes have been reported to carry the effector molecules to induce the apoptosis in 
a cancer cell [96]. Similarly, the abundance of GZB suggested (Fig. 6B) that exosome 




trials to confirm. Also, considering the low expression level in D1 Exo, we are currently 
analyzing the proteomic data which has a higher sensitivity and provides more 
comprehensive protein information and help us to understand the unique signals 
transferred by Exo from activated CTLs to naïve CTLs in the future. Furthermore, there 
was a large difference in protein expression, such as flotillin, between Exo and CTL 
lysate (Fig. 6B), supporting that CTL can selectively sort and pack the distinct 
components of exosomes. Understanding the sorting mechanism of the exosome in 
activated CTLs will benefit the future study of improving immune response. It would 
also be interesting to determine what contents of these early secreted exosomes might 
trigger the activation signal cascade. As a result, more candidates of protein markers 
should be tested on the early-secreted Exo to understand the biogenesis and signaling 
pathway in activating CTLs.  
Similar to D3 Exo, D1 Exo triggered bystander activation of CTLs without the 
engagement of the peptide/TCR. D1 Exo stimulated naïve CTLs proliferation while D3 
Exo stimulated more cell division. Both D1 and D3 Exo induced the production of IFN-
γ and GZB although D3 Exo was more powerful than D1 Exo. The increased expression 
of CD25 and CD69 also supported the role of D1 Exo in inducing CTL response (Fig. 
7B). Further understanding of the function of CTLs to directly destruct infected cells 
and evaluation of exosomal effects on a physiological range should be confirmed in 
vivo in the future.  
When treating naïve CTLs with peptide and Exo, although the function of early-
secreted exosomes was weaker than late-secreted exosomes, we still detected that D1 




(Fig. 8A). As the previous observation, the tendency of CD25, GZB and IFN-γ in D1 
Exo was identical to D3 Exo due to increased expression, especially in the treatment 
with low-affinity peptides (Fig. 8B). The early-secreted exosomes also showed 
increasing CD25 expression which will contribute to immense immune response. 
Moreover, both early and late secreted exosomes changed the transcriptional profile of 
CTL. The increment of T-bet expression (Fig. 9) suggested that exosome altered the 
transcriptional profile and more research is needed in the future to identify the 
downstream signal pathway of exosomal stimulation.  
While there are undoubtedly many factors involved in the maintenance of 
robust immune response, our data indicated that the exosomes secreted by CTLs 
activated by strong-affinity peptides could result in communication between CTLs and 
help the activation of low-affinity CTLs. Although the regulation of exosome formation 
and secretion in CTLs is still unknown, we demonstrated that CTLs generated 
exosomes within D1 of stimulation as an immediate immune response to infection. 
Along with time, the secreted-exosomes became more powerful in improving the cell 
expansion and developing the effector function of CTL. To conclude, the research 
provides the first evidence that exosomes derived from 3SI stimulation contribute to 
mount a robust immune response of CTLs treated with the low-affinity peptide. (Fig. 










Figure 10. CTLs stimulated by 3SI with highest-affinity peptide can secret bio-
functional exosomes to communicate and subsequently stimulate the naïve CTLs, 
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